Thelansis

Axial Spondyloarthritis (axSpA) Market Outlook Thelansis’s “Axial Spondyloarthritis (axSpA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Axial Spondyloarthritis (axSpA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

  Axial spondyloarthritis (axSpA), encompassing both ankylosing spondylitis (AS) and non-radiographic axial SpA, is the most prevalent form of chronic inflammatory arthritis affecting the axial skeleton. AS, impacting 0.1–0.5 percent of the population, manifests with inflammatory back pain, radiographic sacroiliitis, excessive spinal bone formation, and a high incidence of HLA–B27. Conversely, non-radiographic axial SpA, while sharing several similarities with AS, lacks advanced sacroiliac joint damage and spinal ankylosis. Symptoms such as arthralgia, stiffness, and restricted flexibility vary widely across patients and throughout the axial SpA spectrum. Additionally, skeletal manifestations may coexist with conditions like uveitis, psoriasis, and inflammatory bowel disease (IBD), significantly impacting patients' physical and social well-being and disrupting daily life. Despite the substantial burden posed by axial SpA, including notable pain, stiffness, and compromised physica...